The U.S. Supreme Court on Monday declined to hear the appeal of former pharmaceutical executive Martin Shkreli that sought to wriggle him out of a $64.6 million judgment for inflating the price of a life-saving drug.

U.S. District Court Judge Denise Cote in 2022 ordered that Shkreli must disgorge the profits pocketed by his company, Vyera Pharmaceuticals, for jacking up the price of Daraprim to more than $700 a pill and blocking industry competition.